Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

SDĚLENÍ

Ministerstva zahraničních věcí,

kterým xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Xx. x. x. a x. 46/2008 Xx. x. x.

Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, že xxx 1. xxxxx 2017 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno schválení xxxxxx xxxxx Přílohy X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xxx xxx 2018 - Xxxxxxxxxxx standard Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx¹⁾.

X novým xxxxxx Přílohy I xxxxxxxx souhlas Parlament Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx o xxxxxxx xxxx Xxxxxxx I Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx I vstoupilo x xxxxxxxx v xxxxxxx s článkem 34 xxxx. 3 Úmluvy xxx 1. xxxxx 2018. Xxx Českou xxxxxxxxx xxxxxxxxx nové xxxxx Přílohy I x xxxxxxxx xxx 5. xxxxxx 2019.

Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx I x xxxxxxxx xxxxxxxx xxxxxx xxxxx Přílohy I xxxxxx xx 1. xxxxx 2017 a xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Xxxxxxxx xxxxx xxxxxx znění Xxxxxxx X x xxxx xxxxxxx xx xxxxxxx xxxxxx se xxxxxxxxx současně.

SVĚTOVÁ

ANTIDOPINGOVÁ

AGENTURA

SVĚTOVÝ XXXXXXXXXXXXX XXXXX

XXXXXX ZAKÁZANÝCH XXXXX X METOD DOPINGU XXX XXX 2018

XXXXXXXXXXX XXXXXXXX

Xxxxxxxxx xxxx Seznamu xxxx spravován XXXX x bude xxxxxxxxxx x xxxxxxxxxx a xxxxxxxxxxxxx.

X případě xxxxxxxxxxx xxxxxxxxx xxxx anglickou x xxxxxxxxxxxx verzí xxxx rozhodující xxxxxxxx xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx xx 1. xxxxx 2018 

XXXXXX XXXXXXXXXX XXXXX A METOD XXXXXXX XXX ROK 2018

XXXXXXX ANTIDOPINGOVÝ XXXXX

Xxxxxx xx 1. xxxxx 2018

XXXXX A XXXXXX XXXXXXXX XXXXX (XXX SOUTĚŽI X MIMO XXXXXX)

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" kromě xxxxx xx xxxxxx S1, X2, S4.4, X4.5 x S6(a) x Xxxxxxxxxx xxxxx X1, X2 a X3.

XXXXXXXX XXXXX

X0. XXXXXXXXXXX LÁTKY

Jakákoliv xxxxxxxxxxxxx xxxxx, xxxxx xxxx zahrnuta v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x není xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. léčiva x preklinickém xxxx xxxxxxxxx stadiu výzkumu xxxx po xxxxxxxx xxxxxxxxxx, syntetické drogy, xxxxx schválené xxxxx xxx xxxxxxxxxxx použití), xx xxxxxxxx stále.

S1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. ANABOLICKÉ XXXXXXXXXX STEROIDY (AAS):

(a) Xxxxxxxx* AAS, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-hydroxy-5α-androst-1-en-17-on);

bolandiol (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (methyltrienolon (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x další látky x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

b. Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol);

androstendion (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx metabolity x xxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx xx ně:

5α-androstan-3α,17α-diol;

5α-androstan-3α,17ß-diol;

5α-androstan-3ß,17α-diol;

5α-androstan-3ß,17ß-diol;

5ß-androstan-3α,17ß-diol;

5α-androst-2-en-17-on;

androst-4-en-3α,17α-diol;

androst-4-en-3α,17ß-diol;

androst-4-en-3ß,17α-diol;

androst-5-en-3α,17α-diol;

androst-5-en-3α,17ß-diol;

androst-5-en-3ß,17α-diol;

4-androstendiol (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (androst-5-en-3,17-dion);

androsteron;

epi-dihydrotestosteron;

epitestosteron;

etiocholanolon;

3ß-hydroxy-5α-androstan-17-on;

7α-hydroxy-DHEA;

7ß-hydroxy-DHEA;

7-keto-DHEA;

19-norandrosteron;

19-noretiocholanolon.

2. Ostatní xxxxxxxxxx látky, zahrnující:

Klenbuterol; xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX, xxxx. xxxxxxx, XXX-4033, xxxxxxx x XXX140); tibolon; xxxxxxx x zilpaterol, xxx ne x xxxxxxxx pouze xx xx.

Xxx účely skupiny xxxx xxxxx: * "xxxxxxxx" xx vztahuje x xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx neprodukuje. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx tělo normálně xxxxxxxxx xxxxxxxxx.

X2. XXXXXXXXX XXXXXXX, RŮSTOVÉ XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

Xxxxxxxxxxx xxxxx a xxxxx látky s xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxxxx erytropoézu, xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

1.1 Agonisté xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx

xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx XXX (XXX-Xx, methoxypolyethylenglykol-epoetin xxxx (CERA)); XXX-xxxxxxxxx xxxxxxxxxx a jejich xxxxxxxxxx (xxxx. XXXX 530 x peginesatid).

1.2 Xxxxxxxxx prostředky hypoxii xxxxxxxxxxxxxx xxxxxxx (HIF), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (XX-4592); xenon.

1.3 Xxxxxxxxxx XXXX, xxxx.

X-11706.

1.4 Xxxxxxxxxx XXX - xxxx (XXX - β), xxxx.

xxxxxxxxxxxx; sotatercept.

1.5 Xxxxxxxx vrozeného xxxxxxxxx xxxxxxxxx. např.

asialo EPO; xxxxxxxxxxxxx XXX.

2. Xxxxxxxxx xxxxxxx x hormonové xxxxxxxxxx

2.1 Choriogonadotropin (XX) x luteinizační hormon (XX) a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxx, deslorelin, gonadorelin, xxxxxxxxx, leuprorelin, xxxxxxxxx x xxxxxxxxxxx, u xxxx.

2.2 Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. kortikorelin.

2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxxxx a xxxxxxxxxx xxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxx xxxxxxxxx hormonu, xxxx. XXX-9604 x xXX 176-191; xxxxxx xxxxxxxxxx xxxxxxx hormon (GHRH) x xxxx xxxxxxx, xxxx. CJC-1295, xxxxxxxxxx x tesamorelin; xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX), xxxx. ghrelin a xxxxxxxx xxxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx (GHRP), xxxx. xxxxxxxxxxxx, XXXX-1, XXXX-2 (pralmorelin), GHRP-3, XXXX-4, XXXX-5, GHRP-6 x xxxxxxxxx.

3. Růstové xxxxxxx x modulátory xxxxxxxxx faktorů, xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxxxx xxxxxxx faktory (XXXx);

xxxxxxxxxxxx růstový faktor (XXX);

xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1) x xxxx xxxxxxx

xxxxxxxxxx růstové xxxxxxx (MGF);

růstový xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX);

xxxxxxxx- β4 x xxxx xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX).

Xxxxx xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx faktorů ovlivňující xxxxxxx xxxx degradaci xxxxxxxx xxxxx, xxxxx x vaziva, krevní xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.

X3. BETA2- AGONISTÉ

Všichni xxxxxxxxxx i xxxxxxxxxxxx xxxx-2 agonisté, včetně xxxxx xxxxxxxxx isomerů, xxxx zakázáni.

Zahrnují (xxx xx x xxxxxxxx xxxxx xx xx):

Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; salmeterol; xxxxxxxxxx; xxxxxxxxxxx; vilanterol.

Výjimkou xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x oddělených xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx během každých 12 hodin xx xxxxxxxxx xxxxx;
• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx dávka 54 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 mikrogramů xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x xxxx x koncentraci vyšší xxx 1000 ng/ml x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx než 40 xx/xx nebude xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx považována xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxxxxxxxx xxxxxx (x xxxxxxxx) xxxxx, než xxxx xxxxxxx xxxxxxxxx xxxxx.

X4. XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx a metabolické xxxxxxxxxx:

1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, ale ne x omezením xxxxx xx xx.

2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), zahrnující:

Raloxifen;

xxxxxxxxx;

xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx zahrnující:

Cyklofenil;

fulvestrant;

klomifen, ale xx s xxxxxxxx xxxxx na ně.

4. Xxxxx modifikující xxxxxx(x) xxxxxxxxxx včetně inhibitorů xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (AMPK), např. XXXXX; x Xxxxxxxx Xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. 2-(2-xxxxxx-4-((4-xxxxxx-2-(4-(xxxxxxxxxxxxxxx)xxxxxx)xxxxxxx-5-xx)xxxxxxxxxx)xxxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516);

5.2 xxxxxxxx a xxxxxxxx xxxxxxxx;

5.3 xxxxxxxxx;

5.4 trimetazidin.

S5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx xxxx xxxxxxxx, xxxxxx xxxx xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; xxxxxxxxxxxxxxx (xxxx. xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx a xxxxxxxxx); xxxxxxxxxx, xxx xx x omezením xxxxx xx xx.

• Xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxx; indapamid; xxxxxxxx; xxxxxxxx etakrynová; xxxxxxxxx; xxxxxxxxxxxxx; thiazidy (např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, chlorothiazid); xxxxxxxxxx x xxxxxxx (xxxx. tolvaptan), xxx xx x xxxxxxxx xxxxx xx ně.

S xxxxxxxx:

• xxxxxxxxxxxx; xxxxxxxxx x xxxxxx xxxxxx inhibitorů xxxxxxxxxxxxxx (xxxx. dorzolamidu x brinzolamidu)

• Lokálního xxxxxx xxxxxxxxxxxx pro xxxxx xxxxxxxxx

Xxxxx xxxxxxxxxxx množství xxxxx se xxxxxxxxxx xxxxxxxx xxxxxxx (tj. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Xxx Soutěži xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, bude xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx, pokud Xxxxxxxxx nemá xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) xx xxxx látku xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx diuretikum xxxx xxxxx maskovací xxxxx.

XXXXXXXX METODY

M1. XXXXXXXXXX X XXXX X XXXXXXXX KOMPONENTAMI

Zakázané xx xxxxxxxxxxx:

1. Xxxxxx nebo xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx xxxx červených xxxxxxx x xxx xxxxxxxxx xxxxxxxx jakéhokoliv xxxxxx xx xxxxxxxxx xxxxxxx.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. krevní xxxxxxxx xxxxxxxx na hemoglobinu x xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx a efaproxiral (XXX13), xxx ne x omezením pouze xx xx. Inhalační xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx komponentami xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) moči, xxx ne x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx celkem 100 xx za 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx v xxxxxxx xxxxxxxxxxxx zákroků, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx diagnostických xxxxx.

X3. XXXXXX XXXXXX

X důvodu xxxxxxxxxx xx zvýšení xxxxxxxxxxx výkonu xx xxxxxxxx následující:

1. Použití xxxxxxxx nukleových kyselin xxxx jejich xxxxxxx;

2. Xxxxxxx xxxxxxxxx produkovaných xxxxxxxxx, vytvořených k xxxxxxxxxxx xxxxxxxx xxxxxx x/xxxx x xxxxxxxxxxxx xxxx xxxxxxxxxxxx regulaci xxxxxx xxxxxxx.

3. Použití xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx;

XXXXX A XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 xx S5 x X1 až X3 xxxxxxxxx xxxx

xxxx Xxx Xxxxxxx xxxxxxxx i xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx včetně xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. x- a X-, xxxx xxxxxxxx.

Xxxxxxxxxxx zahrnují:

(a) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx uvedeno x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx stimulancia.

Zahrnují (ale xx x xxxxxxxx xxxxx na xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx x jeho xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (parahydroxyamfetamin);

isomethepten;

katin**;

katinon x xxxx analoga (xxxx. xxxxxxxx, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (metylhexanamin);

niketamid;

norfenefrin;

oktopamin;

oxilofrin (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

S výjimkou:

• klonidinu

• derivátů xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx/xxxxxx použití x stimulancií xxxxxxxxxx xx Monitorovacího xxxxxxxx xxx xxx 2018*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, nikotin, xxxxxxxxx x synefrin: Xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2018 a xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx: je xxxxxxxx xxxxx xxx xxxxxxxxxxx vyšší než 5 xxxxxxxxxx v 1 ml moči.

*** Xxxxxxx a xxxxxxxxxxxxx: xxxx xxxxxxxx při xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.

**** Xxxxxxxxx (xxxxxxxxx): není xxxxxxx při lokálním xxxxxx, xxxx. nosní, xxxx aplikace xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx anestetiky.

***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x moči je xxxxx xxx 150 xxxxxxxxxx xx mililitr.

S7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx jsou xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx x jeho xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. KANABINOIDY

Následující kanabinoidy xxxx xxxxxxxx:

• Xxxxxxxx xxxxxxxxxxx, xxxx. hašiš, xxxxxx x xxxxxxxxx.

• Xxxxxxxxxx xxxxxxxxxxx, xxxx. delta9-tetrahydrokanabinol (THC) x xxxxxxx xxxxxxxxxxxxxx.

Xxxxx: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, rektálně, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx zakázané.

Včetně, xxx ne x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX XXXXXXXX V URČITÝCH XXXXXXXX

X1. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx v xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx, a xxx xx xx xxxxxxxx x Mimo xxxxxx.

• Xxxxxxxxxxxx xxxxx (FIA)

• Billiard (všechny xxxxxxxxxx) (WCBS)

• Golf (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, x xxxxxxxxx X-xxxxx x "xxx xxx"

• Xxxxxxxx sporty (xxxxxxxxx potápění) (XXXX) x xxxxxxxxxxxx konstantní xxxx x ploutvemi xxxx xxx ploutví, xxxxxxxxx xxxxx x xxxxxxxxx nebo bez xxxxxxx, xxxx xxxxxxxxx, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx xxxxx, střelba xxxxxxxx xx xxxx x xxxxxxxxxx xxxx.

• Xxxxxxx (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx ne x xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx předpis č. 36/2019 Xx. x. x. nabyl xxxxxxxxx xxxx 26.7.2019.

Xxxxxx xxxxxxx x. 36/2019 Xx. x. x. byl xxxxxx xxxxxxx xxxxxxxxx č. 32/2023 Sb. m. s. s xxxxxxxxx xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx jiných xxxxxxxx xxxxxxxx v xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se jich xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.

1) Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx, xxxxxxx xxx 19. října 2005 x Paříži, byla xxxxxxxxx v xxxxxxxxx xxxxx x s xxxxxxxxx xx českého xxxxxx xxx č. 58/2007 Sb. m. s.

Nové xxxxx xxxxxxxx Xxxxxx xx xxxxxxx xxxxxx xxxx xxxxxxxxx pod č. 46/2008 Sb. m. s.